Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certepetide + FOLFIRINOX in Pancreatic and Colorectal Cancers
NCT05121038Phase 2Active, not recruiting
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial of certepetide in pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma and appendiceal adenocarcinoma. Started Oct 2021; status: active, not recruiting.
02
Drugs
certepetide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal adenocarcinomaappendiceal adenocarcinoma
Beyond the preview
Go deeper on NCT05121038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121038.